DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Sponsor
Boehringer Ingelheim
Study ID
NCT03807440
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin — DRUG
    Empagliflozin
  • Sodium Glucose Transporter 2 inhibitor — DRUG
    Sodium Glucose Transporter 2 inhibitor
  • Dipeptidyl-peptidase 4 inhibitor — DRUG
    Dipeptidyl-peptidase 4 inhibitor
  • Glucagon-like peptide 1 agonist — DRUG
    Glucagon-like peptide 1 agonist

Study Details

This is a non-interventional study using existing data including medical chart review.

Key Dates

Start date
Aug 26, 2019
Status verified
Feb 2023
Primary completion
Aug 31, 2021
Completion
Aug 31, 2021

Study Design

Enrollment
4,083 participants (actual)

Arms

  • Arm: Subjects with Diabetes Mellitus, Type 2

Primary Outcome Measure

Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist [ Time Frame: At study index date 1 (i.e. between September 2018 and December 2018). ]

Related Studies